Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis
暂无分享,去创建一个
[1] R. Sutter,et al. Update on Vaccine-Derived Polioviruses — Worldwide, January 2017–June 2018 , 2016, MMWR. Morbidity and mortality weekly report.
[2] M. Pallansch,et al. Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems , 2017, Food and Environmental Virology.
[3] A. Hinman,et al. Transition Planning For After Polio Eradication , 2017, The Journal of infectious diseases.
[4] O. Diop,et al. Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017 , 2017, MMWR. Morbidity and mortality weekly report.
[5] A. Timen,et al. Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017 , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[6] Update on vaccine-derived polioviruses worldwide, January 2016–June 2017. , 2017, Releve epidemiologique hebdomadaire.
[7] L. Hampton,et al. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. , 2016, MMWR. Morbidity and mortality weekly report.
[8] K. Thompson,et al. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use , 2016, BMC Infectious Diseases.
[9] K. Thompson,et al. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation , 2016, BMC Infectious Diseases.
[10] M. Pallansch,et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame , 2016, BMC Infectious Diseases.
[11] M. Pallansch,et al. An economic analysis of poliovirus risk management policy options for 2013–2052 , 2015, BMC Infectious Diseases.
[12] M. Pallansch,et al. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs , 2015, BMC Infectious Diseases.
[13] Javier Martin,et al. Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative , 2015, PLoS pathogens.
[14] G. Armstrong,et al. Possible Eradication of Wild Poliovirus Type 3 — Worldwide, 2012 , 2014, MMWR. Morbidity and mortality weekly report.
[15] M. Roivainen,et al. Role of environmental poliovirus surveillance in global polio eradication and beyond , 2011, Epidemiology and Infection.
[16] Kimberly M Thompson,et al. Global Surveillance and the Value of Information: The Case of the Global Polio Laboratory Network , 2006, Risk analysis : an official publication of the Society for Risk Analysis.
[17] Kimberly M Thompson,et al. Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication , 2006, Risk analysis : an official publication of the Society for Risk Analysis.
[18] David Heymann. Global polio eradication initiative. , 2006, Bulletin of the World Health Organization.
[19] Guidelines for environmental surveillance of poliovirus circulation , 2003 .
[20] Global eradication of poliomyelitis by the year 2000. , 1988, Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada.